These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23223496)

  • 1. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole.
    Yue Q; Mulder T; Rudewicz PJ; Solon E; Budha N; Ware JA; Lyssikatos J; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2013 Feb; 41(2):508-17. PubMed ID: 23223496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
    Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
    Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
    Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Mechanism of Decyanation of GDC-0425 by Cytochrome P450.
    Takahashi RH; Halladay JS; Siu M; Chen Y; Hop CE; Khojasteh SC; Ma S
    Drug Metab Dispos; 2017 May; 45(5):430-440. PubMed ID: 28188299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
    Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
    Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
    Prakash C; Kamel A; Anderson W; Howard H
    Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83.
    Patel DK; Lewis RP; Hinton ML; Schroeder DH; Shockcor JP; Johnson RL; Sigel CW
    Drug Metab Dispos; 1993; 21(1):62-70. PubMed ID: 8095228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male rats.
    Nassar AF; Wisnewski A; King I
    Xenobiotica; 2015; 45(8):711-21. PubMed ID: 25798740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Krieter PA; Colletti AE; Lyszack E; Rosegay A; Dean D; Luffer-Atlas D; Miller RR; Cioffe C; Chiu SH
    Drug Metab Dispos; 1996 Dec; 24(12):1369-77. PubMed ID: 8971144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
    Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
    Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
    Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.